# A Research Study of How Different Doses of a New Medicine NNC0148-0287 C (Insulin 287) Work on the Blood Sugar in People With Type 1 Diabetes When it is Taken Once a Week

> **NCT03723772** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 66 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** Insulin icodec
- **DRUG:** IGlar U100

## Key facts

- **NCT ID:** NCT03723772
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-29
- **Primary completion:** 2020-06-26
- **Final completion:** 2020-06-26
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2025-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03723772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03723772, "A Research Study of How Different Doses of a New Medicine NNC0148-0287 C (Insulin 287) Work on the Blood Sugar in People With Type 1 Diabetes When it is Taken Once a Week". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03723772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*